MILLENNIUM AND J&J BEGIN STUDY OF VELCADE

Millennium Pharmaceuticals and Johnson & Johnson (J&J) have launched a three-arm, randomized, Phase II study of Velcade and pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer who have failed prior chemotherapy treatment.

The study will assess the potentially additive benefits of combining the activity of two targeted therapies with different mechanisms of action. Also already underway is a two-arm, randomized, Phase II study of Velcade in combination with erlotinib for patients with locally advanced or metastatic non-small cell lung cancer and a study of single-agent Velcade in relapsed bronchioalveolar carcinoma and adenocarcinoma of the lung.